Factors affecting long-term survival in elderly patients undergoing radiotherapy for esophageal carcinoma.

[esophageal carcinoma]

This study was conducted with the aim to analyze the factors affecting the 1 -, 3 - and 5 -year survival rate of elderly patients with esophageal carcinoma . Between 2004 and 2008 , a total of 371 patients aged ≥70 years treated with radiotherapy alone were enrolled in this study . The clinical characteristics and radiotherapy dose were evaluated by survival rate and the 1 -, 3 - and 5 -year overall survival (OS ) rates were found to be 42 , 13 .2 and 9 .16 %, respectively . The univariate analysis revealed significant differences in T , N , M and clinical stage and radiotherapy dose (all P-values <0 .05 ) and no significant differences in gender (all P-values >0 .05 ). There was a difference in tumor location when only comparing the 3 - and 5 -year OS rates (P =0 .031 and P =0 .025 , respectively ). The multivariate analysis identified clinical stage as an independent factor for the 1 -year OS rate (P =0 .003 ), whereas radiotherapy dose and clinical stage were found to be independent factors for the 3 - and 5 -year OS rates (all P-values 0 .05 ). In the analysis of radiotherapy dose , we observed no significant difference in the 1 -year OS rate between the radiation dose (DT ) >60 Gy and the 50 Gy ≤DT <60 Gy groups (P =0 .363 ); however , there were statistically significant differences in the 3 -year OS rate between the 50 Gy ≤DT <60 Gy and the other groups (P =0 .039 and P =0 .032 ); there were no significant differences in the 5 -year OS rate among the dose groups (all P-values >0 .05 ). In conclusion , according to the findings of this retrospective study , radiotherapy alone for elderly patients with esophageal cancer does not appear to be acceptable and there is a need for a more effective treatment . T , N , M and clinical stage and radiotherapy dose were identified as factors significantly affecting the 1 -, 3 - and 5 -year OS in elderly patients with esophageal carcinoma , although a higher radiotherapy dose with normal fractionation did not appear to improve the OS rate .

Diseases
Validation

Diseases presenting "cancer" symptom

achondroplasia

acute rheumatic fever

adrenal incidentaloma

alpha-thalassemia

benign recurrent intrahepatic cholestasis

cadasil

canavan disease

carcinoma of the gallbladder

cholangiocarcinoma

coats disease

congenital adrenal hyperplasia

congenital diaphragmatic hernia

cowden syndrome

cushing syndrome

cutaneous mastocytosis

dedifferentiated liposarcoma

dystrophic epidermolysis bullosa

epidermolysis bullosa simplex

erdheim-chester disease

erythropoietic protoporphyria

esophageal adenocarcinoma

esophageal carcinoma

esophageal squamous cell carcinoma

familial hypocalciuric hypercalcemia

familial mediterranean fever

gm1 gangliosidosis

heparin-induced thrombocytopenia

hereditary cerebral hemorrhage with amyloidosis

hirschsprung disease

hodgkin lymphoma, classical

inclusion body myositis

junctional epidermolysis bullosa

kabuki syndrome

kallmann syndrome

kindler syndrome

lamellar ichthyosis

liposarcoma

locked-in syndrome

lymphangioleiomyomatosis

monosomy 21

neuralgic amyotrophy

oculocutaneous albinism

oligodontia

oral submucous fibrosis

papillon-lefèvre syndrome

pendred syndrome

pleomorphic liposarcoma

primary effusion lymphoma

proteus syndrome

pyomyositis

pyruvate dehydrogenase deficiency

severe combined immunodeficiency

sneddon syndrome

systemic capillary leak syndrome

triple a syndrome

von hippel-lindau disease

waldenström macroglobulinemia

well-differentiated liposarcoma

werner syndrome

wiskott-aldrich syndrome

wolf-hirschhorn syndrome

x-linked adrenoleukodystrophy

This symptom has already been validated